Literature DB >> 29678945

ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update.

Giovanni Battista Migliori1,2, Giovanni Sotgiu3,2, Senia Rosales-Klintz4,2, Rosella Centis1,2, Lia D'Ambrosio1,5,2, Ibrahim Abubakar6, Graham Bothamley7, Jose Antonio Caminero8,9, Daniela Maria Cirillo10, Masoud Dara11, Gerard de Vries12, Stefano Aliberti13, Anh Tuan Dinh-Xuan14, Raquel Duarte15, Fabio Midulla16, Ivan Solovic17, Dragan R Subotic18, Massimo Amicosante19, Ana Maria Correia20, Andra Cirule21, Gina Gualano22, Heinke Kunst23, Fabrizio Palmieri22, Vija Riekstina24, Simon Tiberi23,25, Remi Verduin26, Marieke J van der Werf4,2.   

Abstract

The International Standards for Tuberculosis Care define the essential level of care for managing patients who have or are presumed to have tuberculosis, or are at increased risk of developing the disease. The resources and capacity in the European Union (EU) and the European Economic Area permit higher standards of care to secure quality and timely TB diagnosis, prevention and treatment. On this basis, the European Union Standards for Tuberculosis Care (ESTC) were published in 2012 as standards specifically tailored to the EU setting. Since the publication of the ESTC, new scientific evidence has become available and, therefore, the standards were reviewed and updated.A panel of international experts, led by a writing group from the European Respiratory Society (ERS) and the European Centre for Disease Prevention and Control (ECDC), updated the ESTC on the basis of new published evidence. The underlying principles of these patient-centred standards remain unchanged. The second edition of the ESTC includes 21 standards in the areas of diagnosis, treatment, HIV and comorbidities, and public health and prevention.The ESTC target clinicians and public health workers, provide an easy-to-use resource and act as a guide through all the required activities to ensure optimal diagnosis, treatment and prevention of TB. The content of this work is copyright of the authors or their employers. Design and branding are copyright ©ERS 2018.

Entities:  

Mesh:

Year:  2018        PMID: 29678945     DOI: 10.1183/13993003.02678-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  16 in total

1.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

Review 2.  Advanced imaging tools for childhood tuberculosis: potential applications and research needs.

Authors:  Sanjay K Jain; Savvas Andronikou; Pierre Goussard; Sameer Antani; David Gomez-Pastrana; Christophe Delacourt; Jeffrey R Starke; Alvaro A Ordonez; Patrick Jean-Philippe; Renee S Browning; Carlos M Perez-Velez
Journal:  Lancet Infect Dis       Date:  2020-06-23       Impact factor: 25.071

3.  Clinical standards for the assessment, management and rehabilitation of post-TB lung disease.

Authors:  G B Migliori; F M Marx; N Ambrosino; E Zampogna; H S Schaaf; M M van der Zalm; B Allwood; A L Byrne; K Mortimer; R S Wallis; G J Fox; C C Leung; J M Chakaya; B Seaworth; A Rachow; B J Marais; J Furin; O W Akkerman; F Al Yaquobi; A F S Amaral; S Borisov; J A Caminero; A C C Carvalho; D Chesov; L R Codecasa; R C Teixeira; M P Dalcolmo; S Datta; A-T Dinh-Xuan; R Duarte; C A Evans; J-M García-García; G Günther; G Hoddinott; S Huddart; O Ivanova; R Laniado-Laborín; S Manga; K Manika; A Mariandyshev; F C Q Mello; S G Mpagama; M Muñoz-Torrico; P Nahid; C W M Ong; D J Palmero; A Piubello; E Pontali; D R Silva; R Singla; A Spanevello; S Tiberi; Z F Udwadia; M Vitacca; R Centis; L D Ambrosio; G Sotgiu; C Lange; D Visca
Journal:  Int J Tuberc Lung Dis       Date:  2021-10-01       Impact factor: 3.427

4.  Long-term efficacy of 6-month therapy with isoniazid and rifampin compared with isoniazid, rifampin, and pyrazinamide treatment for pleural tuberculosis.

Authors:  José Francisco García-Rodríguez; N Valcarce-Pardeiro; H Álvarez-Díaz; A Mariño-Callejo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-03       Impact factor: 3.267

5.  Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study.

Authors:  Daan J Touw; Giovanni B Migliori; Jan-Willem Alffenaar; Simone Hj van den Elsen; Marieke Gg Sturkenboom; Onno Akkerman; Linda Barkane; Judith Bruchfeld; Geoffrey Eather; Scott K Heysell; Henadz Hurevich; Liga Kuksa; Heinke Kunst; Johanna Kuhlin; Katerina Manika; Charalampos Moschos; Stellah G Mpagama; Marcela Muñoz Torrico; Alena Skrahina; Giovanni Sotgiu; Marina Tadolini; Simon Tiberi; Francesca Volpato; Tjip S van der Werf; Malcolm R Wilson; Joaquin Zúñiga
Journal:  BMJ Open       Date:  2020-06-16       Impact factor: 2.692

6.  Predictors of Initial Smear-Negative Active Pulmonary Tuberculosis with Acute Early Stage Lung Injury by High-Resolution Computed Tomography and Clinical Manifestations: An Auxiliary Model in Critical Patients.

Authors:  Jun-Jun Yeh
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

7.  Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis.

Authors:  Maria Musso; Silvia Mosti; Gina Gualano; Paola Mencarini; Rocco Urso; Piero Ghirga; Alessia Rianda; Franca Del Nonno; Delia Goletti; Fabrizio Palmieri
Journal:  BMC Infect Dis       Date:  2019-10-22       Impact factor: 3.090

8.  Profiling the mRNA and miRNA in Peripheral Blood Mononuclear Cells in Subjects with Active Tuberculosis.

Authors:  Dan Cao; Ju Wang; Zhongkang Ji; Yanwan Shangguan; Wanru Guo; Xuewen Feng; Kaijin Xu; Jiezuan Yang
Journal:  Infect Drug Resist       Date:  2020-11-23       Impact factor: 4.003

9.  Management of Tuberculosis: Are the Practices Homogeneous in High-Income Countries?

Authors:  Frédéric Méchaï; Hugues Cordel; Lorenzo Guglielmetti; Alexandra Aubry; Mateja Jankovic; Miguel Viveiros; Miguel Santin; Delia Goletti; Emmanuelle Cambau
Journal:  Front Public Health       Date:  2020-09-04

10.  Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020.

Authors:  Giovanni Battista Migliori; Pei Min Thong; Onno Akkerman; Jan-Willem Alffenaar; Fernando Álvarez-Navascués; Mourtala Mohamed Assao-Neino; Pascale Valérie Bernard; Joshua Sorba Biala; François-Xavier Blanc; Elena M Bogorodskaya; Sergey Borisov; Danilo Buonsenso; Marianne Calnan; Paola Francesca Castellotti; Rosella Centis; Jeremiah Muhwa Chakaya; Jin-Gun Cho; Luigi Ruffo Codecasa; Lia D'Ambrosio; Justin Denholm; Martin Enwerem; Maurizio Ferrarese; Tatiana Galvão; Marta García-Clemente; José-María García-García; Gina Gualano; José Antonio Gullón-Blanco; Sandra Inwentarz; Giuseppe Ippolito; Heinke Kunst; Andrei Maryandyshev; Mario Melazzini; Fernanda Carvalho de Queiroz Mello; Marcela Muñoz-Torrico; Patrick Bung Njungfiyini; Domingo Juan Palmero; Fabrizio Palmieri; Pavilio Piccioni; Alberto Piubello; Adrian Rendon; Josefina Sabriá; Matteo Saporiti; Paola Scognamiglio; Samridhi Sharma; Denise Rossato Silva; Mahamadou Bassirou Souleymane; Antonio Spanevello; Eva Tabernero; Marina Tadolini; Michel Eke Tchangou; Alice Boi Yatta Thornton; Simon Tiberi; Zarir F Udwadia; Giovanni Sotgiu; Catherine Wei Min Ong; Delia Goletti
Journal:  Emerg Infect Dis       Date:  2020-09-11       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.